Event Details

Focal One^® has received regulatory clearance and is marketed in the United States, Europe, Canada, Korea, Russia, Brazil and other countries. In the United States, Focal One^® is indicated for the ablation of prostate tissue. Focal One^® is a registered trademark of EDAP TMS.

EDAP TMS S.A., the issuer of record for the Company's publicly traded securities, is evolving its corporate brand to FocalTherics to better reflect its focused therapeutic ultrasound strategy and long-term growth vision. While the Company will continue to operate under its legal name, EDAP TMS S.A., it now does business as FocalTherics across its investor and corporate communications. This brand transition aligns the Company's identity with its expanding innovation portfolio while maintaining continuity, transparency, and regulatory compliance for shareholders. All historical filings, disclosures, and governance materials remain attributable to EDAP TMS S.A., ensuring clarity and consistency throughout this evolution.